Cargando…

SYST-02 PHASE ⅡB CLINICAL TRIAL OF NEOADJUVANT CHEMOTHERAPY REVERSING GLIOMA STEM CELLS CHEMORESISTANCE IN NEWLY DIAGNOSED GBM WITH MGMT PROMOTER UNMETHYLATION

PURPOSE: To evaluate clinical efficacy and safety of combination of nicardipine and valproic acid on temozolomide (TMZ) neoadjuvant chemotherapy targeting on glioma stem cells (GSCs) in newly diagnosed glioblastoma multiforme (GBM) patients with O(6)-methylguanine-DNA-methyltransferase (MGMT) promot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Jun, Wang, Liping, Chen, Yanming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354196/ http://dx.doi.org/10.1093/noajnl/vdac078.081

Ejemplares similares

SYST-11 PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM
por: Chen, Zhongping, et al.
Publicado: (2022)

SYST-08. A phase II trial of concurrent Sunitinib, Temozolomide and Radiation Therapy followed by adjuvant Temozolomide for newly diagnosed Glioblastoma patients with an unmethylated MGMT gene promoter (A01-M121-11A, McG1132)
por: Faye, Mame Daro, et al.
Publicado: (2021)

SYST-10 CSNO2012001 STUDY: A PHASE III TRIAL ON ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY WITH OR WITHOUT INTERFERON-ALPHA IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS
por: Chen, Zhongping, et al.
Publicado: (2022)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

IM-2 Possibility of immunotherapy for the glioblastoma patients with O6-methyl-guanine DNA methyltransferase (MGMT) expression or promoter unmethylated
por: Kushihara, Yoshihiro, et al.
Publicado: (2021)

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
por: Omuro, Antonio, et al.
Publicado: (2022)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme
por: Kirstein, Anna, et al.
Publicado: (2020)

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
por: Van Gool, Stefaan W., et al.
Publicado: (2022)

SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA
por: Odia, Yazmin, et al.
Publicado: (2022)

Homogeneous MGMT Immunoreactivity Correlates with an Unmethylated MGMT Promoter Status in Brain Metastases of Various Solid Tumors
por: Ingold, Barbara, et al.
Publicado: (2009)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

SYST-32 A NOVEL APPROACH TO TARGET TREG-MEDIATED IMMUNOSUPPRESSION IN GBM
por: Pant, Ayush, et al.
Publicado: (2023)

Lomeguatrib Increases the Radiosensitivity of MGMT Unmethylated Human Glioblastoma Multiforme Cell Lines
por: Kirstein, Anna, et al.
Publicado: (2021)

SYST-04 PRELIMINARY REPORT OF A CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICIENCY OF NEOADJUVANT CAMRELIZUMAB AND APATINIB IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS: A PROSPECTIVE, PHASE II, SINGLE-ARM STUDY
por: Lin, Fuhua, et al.
Publicado: (2022)

Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM
por: Shah, Nameeta, et al.
Publicado: (2011)

A case study of a long-term glioblastoma survivor with unmethylated MGMT and hypermutated genotype
por: Jue, Toni Rose, et al.
Publicado: (2019)

Syst
por: Vialettes, H
Publicado: (1971)

SYST-01 MULTI-INSTITUTIONAL RANDOMIZED TRIAL COMPARING CANCER STEM CELL-TARGETED VS PHYSICIAN-CHOICE TREATMENTS IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS (NCT03632135)
por: Sengupta, Soma, et al.
Publicado: (2022)

SYST-12 D2C7 CAR: A NOVEL CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOMA AND BRAIN METASTASES
por: Wilkinson, Daniel, et al.
Publicado: (2022)

Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
por: Sasaki, Takahiro, et al.
Publicado: (2019)

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
por: Alnahhas, Iyad, et al.
Publicado: (2020)

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
por: Chai, Rui-Chao, et al.
Publicado: (2019)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION
por: Leighl, Natasha, et al.
Publicado: (2022)

SYST-08 SURVIVAL ANALYSIS OF METASTATIC MELANOMA PATIENTS WITH BRAIN METASTASIS USING SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)
por: Stahl, Caleb, et al.
Publicado: (2022)

TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA
por: Lita, Adrian, et al.
Publicado: (2021)

Immune-Related lncRNA Risk Signatures Predict Survival of IDH Wild-Type and MGMT Promoter Unmethylated Glioblastoma
por: Li, Xiaozhi, et al.
Publicado: (2020)

Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis
por: Alnahhas, Iyad, et al.
Publicado: (2021)

SYST-03 INCIDENCE AND SURVIVAL OF PATIENTS WITH INTRACRANIAL METASTATIC DISEASE AND ERBB2-POSITIVE GASTROINTESTINAL CANCERS: A RETROSPECTIVE COHORT STUDY
por: Sherman, Madison, et al.
Publicado: (2022)

Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review
por: Baro, Valentina, et al.
Publicado: (2022)

Treatment of unmethylated MGMT-promoter recurrent glioblastoma with cancer stem cell assay-guided chemotherapy and the impact on patients’ healthcare costs
por: Ranjan, Tulika, et al.
Publicado: (2023)

SYST-25 MICROGLIA-SECRETED LIPID SPECIES DRIVE GLIOMA INVASION
por: Pallares-Moratalla, Carla, et al.
Publicado: (2023)

SYST-09 IMPACT OF END-STAGE RENAL DISEASE AND CONCOMITANT DIALYSIS ON THE EFFICACY OF IMMUNOTHERAPY IN BRAIN METASTASES PATIENTS: A PROPENSITY-MATCHED SURVIVAL ANALYSIS
por: Baroz, Angel, et al.
Publicado: (2022)

SYST-05 OPTIMIZING HER2-TARGETED THERAPIES (TT) FOR BREAST CANCER (BC) LEPTOMENINGEAL METASTASES (LM): A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Lazaratos, Anna-Maria, et al.
Publicado: (2022)

Maintaining the unmethylated state
por: Smith, Steven S
Publicado: (2013)

The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis
por: Xing, Wei-kang, et al.
Publicado: (2015)

The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma
por: Villani, Veronica, et al.
Publicado: (2015)

MET-02 Neoadjuvant fractionated stereotactic radiotherapy followed by surgery for large brain metastasis with difficulty in en-block resection
por: Mitsuya, Koichi, et al.
Publicado: (2020)

The SysteMHC Atlas project
por: Shao, Wenguang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lnka1nhmbr36mdib5sh2dah8hb